Skip to main content
Fig. 4 | Renal Replacement Therapy

Fig. 4

From: Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study

Fig. 4

Comparison of urine protein expression status between correlation coefficient + 0.4 < group and correlation coefficient + 0.4 ≧ group in patients receiving BEV combination regimen. Presence or absence of urine protein 1+ or higher: correlation coefficient + 0.4 < group vs correlation coefficient + 0.4 ≧ group, 14 (38%) vs 6 (17%), P = 0.05a). Presence or absence of urinary protein 2+ or higher: correlation coefficient + 0.4 < group vs correlation coefficient + 0.4 ≧ group, 10 (27%) vs 2 (6%), P = 0.01a). a)χ2 test. BEV, bevacizumab

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us